Desert Cancer Care, Inc.
39700 Bob Hope Drive,
Bob Hope Classic Medical Bldg,
Suite 108, Rancho Mirage, CA 92270
Phone: 760-346-7655
Fax: 760-346-3037

Eisenhower Medical Center
39700 Bob Hope Dr.,
Rancho Mirage, CA  92270 

Desert Regional Medical Center
1150 North Indian Canyon Drive
Palm Springs, CA 92262

2009

Sub-investigator – Novartis Pharmaceuticals Corp: A Prospective, Randomized, Muti-Center, Three-arm Trial of the Continued Efficacy and Safety of Zometa in Patients with Documented Bone Metastases from Breast Cancer. Protocol #CZOL446E2352.

2009

Sub-investigator – Gloucester Pharmaceuticals: A Phase II Trial of Romidepsin and Bortezomib for Patients with Multiple Myeloma Relapsed or Refractory Disease,  Protocol #GPI-08-0006.

2009

Sub-investigator – Millennium Pharma: Phase IIIB, Randomized Study of Three Treatment Regimens in Subjects with Previously Untreated Multiple Myeloma who are not Considered Candidates High Dose Chemotherapy and Autologus Stem Cell Transplantation. Velcade, Thalomide & Dexamethasone (VTD) vs Velcade and Dexamethasone (VD) vs Velcade, Melphalan and Prednisone (VMP),  Protocol #C05009

2009

Sub-investigator – Oncotherapeutics: A  Phase II Study of Pegylated Liposomal Doxorubicin, Bortezomib and Dexamethasone (DVD) for Patients With Newly Diagnosed Multiple Myeloma, Protocol #X05272/DOIXILMMY2010.

2009

Principa Investigator – Sanofi Aventis U.S.,Inc.: A Multinational, Randomized, Double- Blind Study Comparing the Efficacy of Aflibercept Once every 2 Weeks Versus Placebo in Patients Treated with Gemcitabine for Metastatic Pancreatic Cancer, Protocol #EFC10547(Vanilla).

2008-2009

Sub-investigator – Angen Inc.: An Open-Label, Multi Center, Phase 2 Safety and Efficacy Study of Denosumab (AMG 162) in Subjects with Recurrent or Unresectable Giant Cell Tumor (GCT) of Bone, Protocol #20040215.

2008-2009

Sub-investigator – AOI Pharmacy Inc.: Sarcoma Aliance for Research Through Collaboration (SARC) Multicenter Trial: A Phase II Trial of Perifosine in Patients with Chemo-insensitive Sarcoma, Protocol #Perfosine #214.

2008-2009

Sub-investigator – SARC: A Multicenter, Open Label Single Arm Study of YONDELIS
(trabeetidin) for Subjects with Locally Advanced or Metastatic Soft Tissue Sarcoma Who 
Have Relapsed or Are Refractory to Standard of Care Treatment, Protocol #JOHNS006/05-045.

2008-2009

Sub-investigator – Amgen Inc.:  A Phase 1b/2 Study to Evaluate the safety and Efficacy   of AmG 655 or AmG 479 in Combination with Gemcitabine as First-Line Therapy for Metastatic Pancreatic Cancer, Protocol #20060323. 

2008-2009

Sub-investigator – Amgen Inc.:  A Phase 1b/2 Study of AmG 655 in Combination with Doxorurbicin for the First-Line Treatment of Locally Advanced for Metastatic, Unreseetable Soft Tissue Sarcoma, Protocol #20060324. 

2008-2009

Sub-investigator – Ziopharm Oncology – A Phase I Study of ZIO-201-T in Combination with Doxorurbicin in Subjects with Advanced Refractory Solid Tumors for which no  Standard Therapy Exists and for Whom Treatment with Doxorurbicin is Considered Medically Acceptable.

2008-2009

Sub-investigator – Ziopharm Oncology – Phase IB Study to Evaluate the Biological  Activity of Indibulin Using Positron-Emission Tomography (PET) Scans, Protocol #IBL 1003.

2008-2009

Sub-investigator – Bristol/Myers/Squibh/Sarcoma Alliance for Research Through Collaboration: A Phase II Trial of Dasatinib in Advanced Sarcomas, Protocol #SARC009/PBMS017/07-043.